Journal of the Korean Association of Oral and Maxillofacial Surgeons

The Korean Association of Oral and Maxillofacial Surgeons (대한구강악안면외과학회)
권호 표지
DOI QR코드

DOI QR Code

Drug holiday as a prognostic factor of medication-related osteonecrosis of the jaw

  • Kim, Yoon Ho (Division of Oral and Maxillofacial Surgery, Department of Dentistry, Ajou University School of Medicine) ;
  • Lee, Ho Kyung (Division of Oral and Maxillofacial Surgery, Department of Dentistry, Ajou University School of Medicine) ;
  • Song, Seung Il (Division of Oral and Maxillofacial Surgery, Department of Dentistry, Ajou University School of Medicine) ;
  • Lee, Jeong Keun (Division of Oral and Maxillofacial Surgery, Department of Dentistry, Ajou University School of Medicine)
  • Received : 2014.05.23
  • Accepted : 2014.07.24
  • Published : 2014.10.31
Download PDF
⟨ Previous Next ⟩

Abstract

Objectives: To identify post-treatment prognostic factors for medication-related osteonecrosis of the jaw (MRONJ). Materials and Methods: We evaluated 54 MRONJ patients who visited the Department of Dentistry, Ajou University Hospital, from May 2007 to March 2014. Twenty-one patients were surgically managed with debridement or sequestrectomy and 33 patients were conservatively managed using antibiotics. Correlations of age, sex, stage, bisphosphonate duration and type, and drug holiday with the prognosis of MRONJ were investigated. Correlations were verified by logistic regression analysis and t-tests with a significance level of 0.05. Results: Clinical outcomes were evaluated on the basis of both clinical and radiographic findings. Twelve out of 21 surgically managed patients showed a favorable prognosis and nine patients relapsed. Thirty-one of the 33 conservatively managed patients showed no specific change in prognosis, and two patients worsened. Statistical analyses of the conservative management group did not reveal any correlation of the above factors with the prognosis of conservative management. Drug holiday was the only prognostic factor in the surgical management group (P=0.031 in logistic regression analysis, P=0.004 in t-test). Conclusion: Drug holiday is a prognostic factor in the surgical management of MRONJ. Because the drug holiday in the patients of the poor prognosis group occurred 1.5 to 4 months prior to surgical management, we recommend a drug holiday more than 4 months before surgery.

Keywords

References

  1. Devogelaer JP. Treatment of bone diseases with bisphosphonates, excluding osteoporosis. Curr Opin Rheumatol 2000;12:331-5. https://doi.org/10.1097/00002281-200007000-00017
  2. Medication-related osteonecrosis of the Jaw--2014 update [Internet]. Rosemont (IL): American Association of Oral and Maxillofacial Surgeons [cited 2014 Apr 1]. Available from: http://www.aaoms.org/docs/position_papers/mronj_position_paper.pdf?pdf=MRONJ-Position-Paper.
  3. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003;61:1115-7. https://doi.org/10.1016/S0278-2391(03)00720-1
  4. Mavrokokki T, Cheng A, Stein B, Goss A. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 2007;65:415-23. https://doi.org/10.1016/j.joms.2006.10.061
  5. Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, et al; American Society for Bone and Mineral Research. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007;22:1479-91. https://doi.org/10.1359/jbmr.0707onj
  6. Lee JK, Kim KW, Choi JY, Moon SY, Kim SG, Kim CH, et al. Bisphosphonates-related osteonecrosis of the jaw in Korea: a preliminary report. J Korean Assoc Oral Maxillofac Surg 2013;39:9-13. https://doi.org/10.5125/jkaoms.2013.39.1.9
  7. Korean Endocrine Society, Korean Society of Bone Metabolism, Korean Society of Osteoporosis, Korean Association of Oral and Maxillofacial Surgeons. Bisphosphonate related osteonecrosis of the jaw (BRONJ): position statement of Korea. J Korean Endocr Soc 2009;24:227-30. https://doi.org/10.3803/jkes.2009.24.4.227
  8. Bilezikian JP. Osteonecrosis of the jaw--do bisphosphonates pose a risk? N Engl J Med 2006;355:2278-81. https://doi.org/10.1056/NEJMp068157
  9. Park YJ, Pyo SW, Kim JA, Min JK. A case of avascular necrosis of mandible associated with the use of bisphosphonate in a patient with rheumatoid arthritis and osteoporosis. J Korean Rheum Assoc 2006;13:150-4.
  10. Carlson ER. Management of antiresorptive osteonecrosis of the jaws with primary surgical resection. J Oral Maxillofac Surg 2014; 72:655-7. https://doi.org/10.1016/j.joms.2013.12.007
  11. Thumbigere-Math V, Sabino MC, Gopalakrishnan R, Huckabay S, Dudek AZ, Basu S, et al. Bisphosphonate-related osteonecrosis of the jaw: clinical features, risk factors, management, and treatment outcomes of 26 patients. J Oral Maxillofac Surg 2009;67:1904-13. https://doi.org/10.1016/j.joms.2009.04.051
  12. Ruggiero SL, Fantasia J, Carlson E. Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006;102:433-41. https://doi.org/10.1016/j.tripleo.2006.06.004
  13. Lee HK, Seo MH, Pang KM, Song SI, Lee JK. Comparative study on surgical and conservative management of bisphosphonate-related osteonecrosis of the jaw (BRONJ) in disease stage 2. J Korean Assoc Maxillofac Plast Reconstr Surg 2013;35:302-9.
  14. Stockmann P, Burger M, von Wilmowsky C, Ebker T, Lutz R, Bauersachs A, et al. The outcome after surgical therapy of bisphosphonate-associated osteonecrosis of the jaw--results of a clinical case series with an average follow-up of 20 months. Clin Oral Investig 2014;18:1299-304.
  15. Holzinger D, Seemann R, Klug C, Ewers R, Millesi G, Baumann A, et al. Long-term success of surgery in bisphosphonate-related osteonecrosis of the jaws (BRONJs). Oral Oncol 2013;49:66-70. https://doi.org/10.1016/j.oraloncology.2012.07.008
  16. Graziani F, Vescovi P, Campisi G, Favia G, Gabriele M, Gaeta GM, et al. Resective surgical approach shows a high performance in the management of advanced cases of bisphosphonate-related osteonecrosis of the jaws: a retrospective survey of 347 cases. J Oral Maxillofac Surg 2012;70:2501-7. https://doi.org/10.1016/j.joms.2012.05.019
  17. Mucke T, Koschinski J, Deppe H, Wagenpfeil S, Pautke C, Mitchell DA, et al. Outcome of treatment and parameters influencing recurrence in patients with bisphosphonate-related osteonecrosis of the jaws. J Cancer Res Clin Oncol 2011;137:907-13. https://doi.org/10.1007/s00432-010-0953-1
  18. Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, et al; FLEX Research Group. Effects of continuing or stopping alendronate after 5 years of treatment: the fracture intervention trial long-term extension (FLEX): a randomized trial. JAMA 2006;296:2927-38. https://doi.org/10.1001/jama.296.24.2927

Cited by

  1. Impact of communication between physicians and dentists on the incidence of jaw osteonecrosis caused by bone anti-resorptives vol.32, pp.8, 2016, https://doi.org/10.1080/03007995.2016.1185401
  2. Usability of Surgical Treatment of Stage Ⅱ Medication Related Osteonecrosis of the Jaw vol.43, pp.1, 2014, https://doi.org/10.17779/kaomp.2018.43.1.003
  3. Value of pre-operative CTX serum levels in the prediction of medication-related osteonecrosis of the jaw (MRONJ): a retrospective clinical study vol.10, pp.1, 2014, https://doi.org/10.1007/s13167-019-0160-3
  4. Drug holiday clinical relevance verification for antiresorptive agents in medication-related osteonecrosis cases of the jaw vol.38, pp.1, 2014, https://doi.org/10.1007/s00774-019-01035-7
  5. Pharmacological osteonecrosis in maxillofacial surgery, period 2013-2019 vol.28, pp.None, 2014, https://doi.org/10.20986/resed.2021.3837/2020
  6. A critical assessment of the medication-related osteonecrosis of the jaw classification in stage I patients: a retrospective analysis vol.47, pp.2, 2014, https://doi.org/10.5125/jkaoms.2021.47.2.99
  7. Various Therapeutic Methods for the Treatment of Medication-Related Osteonecrosis of the Jaw (MRONJ) and Their Limitations: A Narrative Review on New Molecular and Cellular Therapeutic Approaches vol.10, pp.5, 2021, https://doi.org/10.3390/antiox10050680
  8. Investigation of the Effectiveness of Surgical Treatment on Maxillary Medication-Related Osteonecrosis of the Jaw: A Literature Review vol.10, pp.19, 2021, https://doi.org/10.3390/jcm10194480
  9. Medication Related Osteonecrosis of the Jaw: 2021 Position Statement of the Korean Society for Bone and Mineral Research and the Korean Association of Oral and Maxillofacial Surgeons vol.28, pp.4, 2014, https://doi.org/10.11005/jbm.2021.28.4.279